Table 1.
Characteristics of COVID‐19 patients with cutaneous manifestations included in the WHOLE and CONFIRMED cohorts
| WHOLE cohort | CONFIRMED cohort | |
|---|---|---|
| Number of COVID‐19 patients, N | 1020 | 480 |
| Confirmed SARS‐CoV‐2 infection, N (%) | 480 (47%) | 480 (100%) |
| Suspected SARS‐CoV‐2 infection, N (%) | 540 (53%) | 0 (0%) |
| Age | ||
| Mean, years (range) | 42.2 (15 days to 98 years) | 48.0 (15 days to 98 years) |
| Not mentioned, N | 161/1020 | 45/480 |
| Sex | ||
| Male, N (%) | 407 (48%) | 174 (48%) |
| Female, N (%) | 438 (52%) | 189 (52%) |
| Not mentioned N | 175/1020 | 117/480 |
| Country | ||
| Belgium, N (%) | 3 (0.3%) | 3 (0.6%) |
| China, N (%) | 10 (1%) | 10 (2%) |
| France, N (%) | 308 (30%) | 57 (12%) |
| Iran, N (%) | 2 (0.2%) | 2 (0.4%) |
| Italy, N (%) | 164 (16%) | 85 (17.8%) |
| Kuwait, N (%) | 2 (0.2%) | 2 (0.4%) |
| Spain, N (%) | 518 (51%) | 308 (64%) |
| Thailand, N (%) | 1 (0.1%) | 1 (0.2%) |
| USA, N (%) | 9 (0.9%) | 9 (2%) |
| Morocco, N (%) | 2 (0.2%) | 2 (0.4%) |
| Indonesia, N (%) | 1 (0.1%) | 1 (0.2%) |
| Cutaneous lesions morphology | ||
| Rash, N (%) | 555 (54%) | 337 (70%) |
| Vesicular/varicelliform, N (%) | 114 (11%) | 80 (17%) |
| Erythematous maculopapular/morbilliform, N (%) | 245 (24%) | 169 (36%) |
| Urticarial/annular/eczematiform, N (%) | 178 (17%) | 76 (14%) |
| Petechial/purpuric, N (%) | 18 (2%) | 12 (3%) |
| Vascular lesions, N (%) | 408 (40%) | 112 (24%) |
| Chilblains, N (%) | 342 (34%) | 53 (11.5%) |
| Transient/livedo reticularis, N (%) | 9 (1%) | 6 (1%) |
| Digital necrosis/ necrotic purpura, N (%) | 57 (5%) | 53 (11.5%) |
| Other findings, N (%) | 57 (6%) | 31 (6%) |
| Herpes recurrence, N (%) | 21 (2%) | 21 (4%) |
| Eruptive cherry haemangioma, N (%) | 8 (1%) | 1 (0.2%) |
| Acral dyshidrosis‐like lesions, N (%) | 20 (2%) | 1 (0.2%) |
| Ecthyma/impetigo, N (%) | 5 (0.5%) | 5 (1%) |
| Coma blisters, N (%) | 2 (0.2%) | 2 (0.4%) |
| Acute generalized exanthematous pustulosis (drug reaction), N (%) | 1 (0.1%) | 1 (0.2%) |
| Cutaneous involvement location | ||
| Trunk, N (%) | 186 (35%) | 125 (53%) |
| Lower limbs (excluding acral lesions), N (%) | 102 (19%) | 43 (18.4%) |
| Upper limbs, N (%) | 56 (10%) | 29 (12.4%) |
| Acral lesions (fingers, toes, hands, heels), N (%) | 322 (60%) | 44 (18.8%) |
| Buttocks, N (%) | 2 (0.2%) | 2 (0%) |
| Mucosa (oral, genitalia), N (%) | 6 (1.3%) | 6 (1.3%) |
| Face/head, N (%) | 26 (5%) | 16 (6.8%) |
| Widespread, N (%) | 26 (5%) | 23 (9.8%) |
| Flexural areas/folds, N (%) | 4 (0.75%) | 4 (1.7%) |
| Not mentioned, N | 485/1020 | 246/480 |
| Cutaneous symptoms | ||
| Itching, N (%) | 347 (73%) | 205 (68%) |
| Burning, N (%) | 66 (14%) | 23 (8%) |
| Pain, N (%) | 91 (19%) | 37 (12.2%) |
| Asymptomatic, N (%) | 62 (13%) | 38 (12.5%) |
| Not mentioned, N | 472/1020 | 177/480 |
| Mean delay of onset of cutaneous manifestations, days (range) | 6.8 (−15 to 25 days) | 6.7 (−15 to 25 days) |
| Mean duration of cutaneous manifestations, days (range) | 9.0 (20 min to 30 days) | 9.0 (20 min to 30 days) |